Browsing by Author "Ducharme, Francine M."

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing : A systematic review
    (2018) Castro Rodríguez, José Antonio; Rodríguez Martínez, Carlos E.; Ducharme, Francine M.
  • No Thumbnail Available
    Item
    Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden
    (2020) Papadopoulos, Nikolaos G.; Custovic, Adnan; Deschildre, Antoine; Mathioudakis, AleXander G.; Phipatanakul, Wanda; Wong, Gary; Xepapadaki, Paraskevi; Agache, Ioana; Bacharier, Leonard; Bonini, Matteo; Castro-Rodriguez, Jose A.; Chen, Zhimin; Craig, Timothy; Ducharme, Francine M.; El-Sayed, Zeinab AWad; Feleszko, Wojciech; Fiocchi, Alessandro; Garcia-Marcos, Luis; Gern, James E.; Goh, Anne; Gomez, Rene MaXimiliano; Hamelmann, Eckard H.; Hedlin, Gunilla; Hossny, Elham M.; Jartti, Tuomas; Kalayci, Omer; Kaplan, Alan; Konradsen, Jon; Kuna, Piotr; Lau, Susanne; Souef, Peter Le; Lemanske, Robert F.; Makela, Mika J.; Morais-Almeida, Manio; Murray, Clare; Nagaraju, Karthik; Namazova-Baranova, Leyla; Garcia, Antonio Nieto; Yusuf, Osman M.; Pitrez, Paulo M. C.; Pohunek, Petr; Beltran, Cesar Fireth Pozo; Roberts, Graham C.; Valiulis, Arunas; Zar, Heather J.
    BACKGROUND: It is unclear whether asthma may affect susceptibility or severity of coronavirus disease 2019 (COVID-19) in children and how pediatric asthma services worldwide have responded to the pandemic.
  • Thumbnail Image
    Item
    Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children
    (2015) Brodlie, Malcolm; Gupta, Atul; Rodríguez Martínez, Carlos E.; Castro Rodríguez, José Antonio; Ducharme, Francine M.; Mckean, Michel C.; Brodlie, Malcolm; Gupta, Atul; Rodríguez Martínez, Carlos E.; Castro Rodríguez, José Antonio; Ducharme, Francine M.; Mckean, Michel C.; Brodlie, Malcolm; Gupta, Atul; Rodríguez Martínez, Carlos E.; Castro Rodríguez, José Antonio; Ducharme, Francine M.; Mckean, Michel C.; Brodlie, Malcolm; Gupta, Atul; Rodríguez Martínez, Carlos E.; Castro Rodríguez, José Antonio; Ducharme, Francine M.; Mckean, Michel C.
  • Thumbnail Image
    Item
    Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO
    (2024) Papadopoulos, Nikolaos G.; Custovic, Adnan; Deschildre, Antoine; Gern, James E.; Nieto Garcia, Antonio; Miligkos, Michael; Phipatanakul, Wanda; Wong, Gary; Xepapadaki, Paraskevi; Agache, Ioana; Arasi, Stefania; El-Sayed, Zeinab Awad; Bacharier, Leonard B.; Bonini, Matteo; Braido, Fulvio; Caimmi, Davide; Castro-Rodriguez, Jose A.; Chen, Zhimin; Clausen, Michael; Craig, Timothy; Diamant, Zuzana; Ducharme, Francine M.; Ebisawa, Motohiro; Eigenmann, Philippe; Feleszko, Wojciech; Fierro, Vincezo; Fiocchi, Alessandro; Garcia-Marcos, Luis; Goh, Anne; Gomez, Rene Maximiliano; Gotua, Maia; Hamelmann, Eckard; Hedlin, Gunilla; Hossny, Elham M.; Ispayeva, Zhanat; Jackson, Daniel J.; Jartti, Tuomas; Jesenak, Milos; Kalayci, Omer; Kaplan, Alan; Konradsen, Jon R.; Kuna, Piotr; Lau, Susanne; Le Souef, Peter; Lemanske, Robert F.; Levin, Michael; Makela, Mika J.; Mathioudakis, Alexander G.; Mazulov, Oleksandr; Morais-Almeida, Mario; Murray, Clare; Nagaraju, Karthik; Novak, Zoltan; Pawankar, Ruby; Pijnenburg, Marielle W.; Pite, Helena; Pitrez, Paulo M.; Pohunek, Petr; Price, David; Priftanji, Alfred; Ramiconi, Valeria; Rivero Yeverino, Daniela; Roberts, Graham; Sheikh, Aziz; Shen, Kun-Ling; Szepfalusi, Zsolt; Tsiligianni, Ioanna; Turkalj, Mirjana; Turner, Steve; Umanets, Tetiana; Valiulis, Arunas; Vijveberg, Susanne; Wang, Jiu-Yao; Winders, Tonya; Yon, Dong Keon; Yusuf, Osman M.; Zar, Heather J.
    Monitoring is a major component of asthma management in children. Regular monitoring allows for diagnosis confirmation, treatment optimization, and natural history review. Numerous factors that may affect disease activity and patient well-being need to be monitored: response and adherence to treatment, disease control, disease progression, comorbidities, quality of life, medication side-effects, allergen and irritant exposures, diet and more. However, the prioritization of such factors and the selection of relevant assessment tools is an unmet need. Furthermore, rapidly developing technologies promise new opportunities for closer, or even "real-time," monitoring between visits. Following an approach that included needs assessment, evidence appraisal, and Delphi consensus, the PeARL Think Tank, in collaboration with major international professional and patient organizations, has developed a set of 24 recommendations on pediatric asthma monitoring, to support healthcare professionals in decision-making and care pathway design. image
  • Thumbnail Image
    Item
    Treatment of asthma in young children: evidence-based recommendations
    (2016) Castro Rodríguez, José Antonio; Custovic, Adnan; Ducharme, Francine M.
    Abstract In the present review, we focus on evidence-based data for the use of inhaled corticosteroids (ICS), leukotriene receptor antagonist (LTRA), long-acting beta2-agonits (LABA) and oral corticosteroids (OCS), with a special emphasis on well-performed randomized clinical trials (RCTs) and meta-analyses of such trials for the chronic management of asthma/wheeze in infants and preschoolers. Results: Seven meta-analyses and 14 RCTs were reviewed. Daily ICS should be the preferred drug for infants/preschoolers with recurrent wheezing, especially in asthmatics. For those with moderate or severe episodes of EVW, the use of high intermittent ICS doses significantly reduce the use of OCS. There is no evidence of effect of intermittent ICS at low-moderate dose in preschoolers with mild EVW episodes. In preschoolers with asthma, there were no significant differences between daily vs. intermittent ICS in terms of asthma exacerbations with insufficient power to conclude to equivalence; however, for other asthma control outcomes, daily ICS works significantly better than intermittent ICS for older children. Daily ICS is superior to daily or intermittent LRTA for reducing symptoms, preventing exacerbations, and improving lung function. No RCTs testing combination therapy with ICS and LABA (or LTRA) were published in infant/preschoolers. Parent-initiation of OCS at the first sign of symptoms is not effective in children with recurrent wheezing episode. In terms of ICS safety, growth suppression is dose and molecule-dependent but it’s effect is not cumulative beyond the first year of therapy and may be associated with some catch-up growth while on or off therapy. Linear growth must be monitored as individual susceptibility to ICS drugs may vary considerably.